Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Gesundheit: Wer soll die Pflege bezahlen? Wirtschaftsrat setzt auf Vermögen und mehr Eigenverantwortung

Die Pflegeversicherung steht finanziell unter Druck. Der Wirtschaftsrat der CDU fordert deshalb einen Kurswechsel: Wer genug Geld hat, soll im Pflegeheim künftig mehr selbst zahlen.

Original German Read in English

Gesundheit: Wer soll die Pflege bezahlen? Wirtschaftsrat setzt auf Vermögen und mehr Eigenverantwortung

Pflege is expensive, and it's only going to get more costly. Already next year, the health ministry predicts a billion-euro shortfall for the nursing insurance. At the same time, the demand for care is rising. The key question is therefore where the necessary money will come from. The new federal health minister, Carsten Linnemann (CDU), must find a solution as soon as possible and launch a nursing reform within the year.

His predecessor Nina Warken (CDU), who has since moved on to the chancellor's office, left a draft for a Nursing Reform Act (NROG) in early June, which proposes cuts. However, this plan is facing resistance, partly from the CDU itself and its coalition partner. Now, the CDU's business council is entering the debate with proposals for nursing care.

In an exclusive six-page position paper for the Handelsblatt, the business association argues that citizens should take more responsibility for their own nursing costs, and that wealth should count more. Wolfgang Steiger, the council's general secretary, doesn't think Warken's plans go far enough. "The measures currently planned mainly aim at short-term stabilization of the nursing insurance finances and thus fall short," he told the Handelsblatt.

Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at handelsblatt.com →

More in Health & Medicine

LG Chem Begins Preclinical Development of Genuv’s Next-Generation Immuno-Oncology Candidate

LG Chem is moving ahead with the development of GNV205, a next-generation immuno-oncology candidate licensed from South Korean biotech company Genuv, as it seeks to strengthen its pipeline of…

  • LG Chem starts preclinical studies for GNV205, a next-gen immuno-oncology drug.
  • GNV205 combines PD-1 antibody with interleukin-2 for targeted immune response.
  • LG Chem acquired exclusive rights to GNV205 in September 2025.

More from Wednesday 19 August →